Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.44 |
| ▸ | CCR3 | P51677 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13163951 | 0.88 | MCHR1 (0.55) | FGFR1FGFR2FGFR3MCHR1CCR3 | |
| SCHEMBL13634183 | 0.88 | ALDH1A1 (0.49) | ALDH1A1FGFR1FGFR2FGFR3MCHR1 | |
| SCHEMBL13162756 | 0.87 | POLB (0.50) | FGFR1FGFR2FGFR3MCHR1CCR3 | |
| SCHEMBL2770332 | 0.87 | ALDH1A1 (0.55) | ALDH1A1FGFR1FGFR2FGFR3MCHR1 | |
| SCHEMBL13162755 | 0.86 | ALDH1A1 (0.52) | ALDH1A1FGFR1FGFR2FGFR3MCHR1 | |
| SCHEMBL13634234 | 0.86 | ALDH1A1 (0.47) | ALDH1A1FGFR1FGFR2FGFR3MCHR1 | |
| SCHEMBL13162753 | 0.86 | ALDH1A1 (0.49) | ALDH1A1FGFR1FGFR2FGFR3MCHR1 | |
| SCHEMBL13638860 | 0.78 | ALDH1A1 (0.45) | ALDH1A1FGFR1FGFR2FGFR3MCHR1 | |
| SCHEMBL2770947 | 0.77 | ALDH1A1 (0.57) | ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL13162819 | 0.75 | KMT2A (0.63) | ALDH1A1KDM4ENPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | ALDH1A1 1659/4885FGFR1 16/4885FGFR2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.